Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.11 USD | -0.18% | +6.70% | -1.69% |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Mar. 25 | Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.69% | 958M | |
-2.27% | 102B | |
+2.54% | 96.09B | |
+2.13% | 22.28B | |
-17.00% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.60% | 16.09B | |
+5.29% | 13.83B | |
+32.94% | 11.97B |
- Stock Market
- Equities
- SAVA Stock
- News Cassava Sciences, Inc.
- B. Riley Lowers Cassava Sciences' Price Target to $58 from $72 to Factor in Increased Pace of Research & Development Expenses; Keeps Buy Rating